RxDoctor Payments Data

Kimberly Collins, PA

Physician Assistant · Raymondville, TXNPI 1043526833

Payments from drug & device makers

$900in general payments, 2019–2025

Across 49 payments — averaging $18.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$113
  • GSK$107
  • Amgen$104
  • AstraZeneca$98
  • Lilly USA, LLC$97
  • Merck$53
  • plus $328 from 12 others

What the payments were for

  • Food & beverage$86796%
  • Education$344%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$900 in reported general payments places this provider in the 60th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$29,290
Medicare patients
48
Services billed
559

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide50$77,384
FarxigaDapagliflozin Propanediol77$74,724
JardianceEmpagliflozin71$62,663
TradjentaLinagliptin57$50,165
OzempicSemaglutide28$43,090
TrulicityDulaglutide27$42,815
EliquisApixaban25$27,881
Tresiba Flextouch U-200Insulin Degludec29$26,357
VraylarCariprazine Hcl17$25,283
JanuviaSitagliptin Phosphate31$22,557
XareltoRivaroxaban15$17,789
Synjardy XrEmpagliflozin/Metformin Hcl23$17,284
Tresiba Flextouch U-100Insulin Degludec23$16,509
KerendiaFinerenone11$14,467
MyrbetriqMirabegron19$12,532

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Synjardy$24$142,635167 claims
Novo NordiskRybelsus, Ozempic$113$120,47478 claims
AstraZenecaFarxiga, Breztri Aerosphere$98$85,30989 claims
Lilly USA, LLCTrulicity$97$42,81527 claims
MerckJanuvia, Janumet Xr$53$28,74346 claims
PfizerEliquis$30$27,88125 claims
AbbVieVraylar$36$25,28317 claims
Johnson & JohnsonXarelto$21$17,78915 claims
BayerKerendia$20$14,46711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Raymondville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →